Alex Y. Chang - Researcher Profile | RDL Research Database

Publications

2 shown

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher , Alex Y. Chang , Purvish M. Parikh +8 more

2005 The Lancet 2086 citations

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch , Marileila Varella‐Garcia , Paul A. Bunn +16 more

Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cance...

2006 Journal of Clinical Oncology 702 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,788
Institution: AstraZeneca (Brazil)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-9578-0323

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.